7 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
27 Feb 24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7:30am
.
USE IN SPECIFIC POPULATIONS
Females of Reproductive Potential
EMPAVELI may cause embryo-fetal harm when administered to pregnant women. Pregnancy
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
8 Jan 24
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
9:07am
embryo-fetal harm when administered to pregnant women. Pregnancy testing is recommended for females of reproductive potential prior to treatment
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
31 Jul 23
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
8:03am
EMPAVELI may cause embryo-fetal harm when administered to pregnant women. Pregnancy testing is recommended for females of reproductive potential prior
- Prev
- 1
- Next